Grace Colón, InCarda CEO

With its eyes set on an IPO raise, In­Car­da un­rolls mid-stage da­ta back­ing in­haled ar­rhyth­mia drug

Work­ing to craft an old ar­ry­th­mia drug in­to a more user-friend­ly in­haled for­mu­la­tion, In­Car­da is ex­pect­ing to use new Phase II da­ta re­vealed Wednes­day as the foun­da­tion of a po­ten­tial IPO raise.

The pro­gram, re­pur­pos­ing the oral and IV drug fle­cainide in­to an in­halant, com­plet­ed the lat­est co­hort of its Phase II study with 50% of pa­tients suc­cess­ful­ly con­vert­ing their ir­reg­u­lar heart­beat episodes back to nor­mal rhythm with­in 90 min­utes, the San Fran­cis­co biotech said. That end­point will be the pri­ma­ry goal in a piv­otal Phase III study, ex­pect­ed to be­gin by the end of Sep­tem­ber.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.